Clinical meetings

← vista completa

Published on October 1, 2008 | http://doi.org/10.5867/medwave.2008.09.1713

Developments in respiratory syncytial virus (RSV) I: pathogenesis

Novedades en virus respiratorio sincicial (VRS) I: patogenia

Karen Messenger C.

This work is licensed under a Creative Commons Attribution 4.0 International License. Esta licencia permite el uso, distribución y reproducción del artículo en cualquier medio, siempre y cuando se otorgue el crédito correspondiente al autor del artículo y al medio en que se publica, en este caso, Medwave.

Authors

Karen Messenger C.

Hospital San Borja Arriarán, Santiago, Chile
Departamento de Pediatría Centro, Facultad de Medicina Universidad de Chile, Santiago, Chile

Figures

Article has no figures.

Forum

No messages

History

Citation Messenger C. K. Developments in respiratory syncytial virus (RSV) I: pathogenesis. Medwave 2008;8(09):e1713 doi: 10.5867/medwave.2008.09.1713

Submission date 01/01/1970

Acceptance date 01/01/1970

Publication date 01/10/2008

Index

Metrics

Not available at the moment.

Notes

References

  1. Black CP. Systematic review of the biology and medical management of RSV Infection. Respir Care. 2003 Mar;48(3):209-31; discussion 231-3. | PubMed
  2. Fisher RG, Gruber WC, Edwards KM, Reed GW, Tollefson SJ, Thompson JM, et al. Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials. Pediatrics. 1997 Feb;99(2):E7. | CrossRef | PubMed
  3. Simoes EA. Environmental and demographic risk factors for respiratory syncytial virus lower respiratory tract disease. J Pediatr. 2003 Nov;143(5 Suppl):S118-26. | CrossRef | PubMed
  4. Meissner HC, Long SS. Respiratory Syncytial Virus Infection and Recurrent Wheezing: A Complex Relationship. J Pediatr. 2007 Jul;151(1):6-7. | CrossRef | PubMed
  5. Hu C, Wedde-Beer K, Auais A, Rodriguez MM, Piedimonte G. Nerve growth factor and nerve growth factor receptors in respiratory syncytial in respiratory syncytial virus-infected lungs. Am J Physiol Lung Cell Mol Physiol. 2002 Aug;283(2):L494-502. | PubMed
  6. Simoes EA, Groothuis JR, Carbonell-Estrany X, Rieger CH, Mitchell I, Fredrick LM, et al. Palivizumab prophylaxis, respiratory syncytial virus, and subsequent recurrent wheezing. J Pediatr. 2007 Jul;151(1):34-42, 42.e1. | PubMed
  7. Castro SM, Guerrero-Plata A, Suarez-Real G, Adegboyega PA, Colasurdo GN, Khan AM, et al. Antioxidant Treatment Amellorates Respiratory Syncytial Virus-Induced Disease and Lung Inflammation. Am J Respir Crit Care Med. 2006 Dec 15;174(12):1361-9. Epub 2006 Sep 28. | PubMed
  8. Bisgaard H. A Randomized Trial of Montelukast in Respiratory Syncytial Virus Postbronchiolitis. Am J Respir Crit Care Med. 2003 Feb 1;167(3):379-83. Epub 2002 Oct 3. | PubMed
  9. Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Inmune Globulin Intravenous for the Prevention on Respiratory Syncytial Virus Infections. Pediatrics 2003; 112:1447-1452.
  10. Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin Prophylaxis. Pediatrics. 1997 Jan;99(1):93-9. | PubMed
  11. Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward. J Clin Virol. 2008 Jan;41(1):38-44 | PubMed
  12. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, et al. Development of Motamizumab, and Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract. J Mol Biol. 2007 May 4;368(3):652-65. Epub 2007 Feb 20. | PubMed